Artificial intelligence is helping doctors and nurses save time and see more patients. However, a Philips survey shows most healthcare work...

Saidou Technology, backed by Seres Group, has launched its AIVA artificial intelligence auto brand. The company is partnering with ByteDanc...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...

Novo Holdings is investing 500 million euros in the new Scaleup Europe Fund. This pan-European fund aims to support technology companies th...

Intel unveiled new AI-focused technologies, strategic collaborations, and next-generation processors at Computex 2026. The company announce...

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...

Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s, Parkinson’s,...

Heads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...

India's dominance in global capability centres is evolving. These hubs are now integrated, managing complex functions beyond support. Risin...

The shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...

Global firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to...

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of ⁠the therap...